ArticleJournal for immunotherapy of cancer2022
Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival.
Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 35 citations in OpenAlex.
- Exploring the Immunomodulatory Effects of Fasting-Mimicking Diet in Healthy Individuals: A Pilot Study.Nutrients · 2026Trial
- Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial.Nature medicine · 2026Trial
- Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma.Oncoimmunology · 2026Article
- Spatial Distribution and Prognostic Value of T Cell Subtypes and Immune Biomarkers in p16-Negative HNSCC.Cells · 2025Article
- Single-cell spatial transcriptomics unravels cell states and ecosystems associated with clinical response to immunotherapy.Journal for immunotherapy of cancer · 2025Article
- Integration of single-cell and bulk RNA sequencing to identify a distinct tumor stem cells and construct a novel prognostic signature for evaluating prognosis and immunotherapy in LUAD.Journal of translational medicine · 2025Article
- Article
- Pan-cancer convergence of tumour-immune microenvironment motifs revealed by CyTOF and imaging mass cytometry.Frontiers in immunology · 2025Review
- NF-κB associated markers of prognosis in early and metastatic triple negative breast cancer.Breast cancer research : BCR · 2024Article
- Activated HLA-DR+CD38+ Effector Th1/17 Cells Distinguish Crohn's Disease-associated Perianal Fistulas from Cryptoglandular Fistulas.Inflammatory bowel diseases · 2024Article
- Transferrin receptor-targeted immunostimulant for photodynamic immunotherapy against metastatic tumors throughActa pharmaceutica Sinica. B · 2024Article
- Monocyte infiltration is an independent positive prognostic biomarker in vulvar squamous cell carcinoma.Cancer immunology, immunotherapy : CII · 2024Article
- [Clinicopathological characteristics of the CD8Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- Article
- CD4Cellular & molecular immunology · 2024Article
- The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases.Frontiers in immunology · 2024Review
- The combined HPV16-E2/E6/E7 T cell response in oropharyngeal cancer predicts superior survival.Cell reports. Medicine · 2023Article
- Predicting HPV association using deep learning and regular H&E stains allows granular stratification of oropharyngeal cancer patients.NPJ digital medicine · 2023Article
- Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target.Clinical and translational medicine · 2023Review
- Human T cells loaded with superparamagnetic iron oxide nanoparticles retain antigen-specific TCR functionality.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundThe composition of the tumor immune microenvironment (TIME) associated with good prognosis generally also predicts the success of immunotherapy, and both entail the presence of pre-existing tumor-specific T cells. Here, the blueprint of the TIME associated with such an ongoing tumor-specific T-cell response was dissected in a unique prospective oropharyngeal squamous cell carcinoma (OPSCC) cohort, in which tumor-specific tumor-infiltrating T cells were detected (immune responsiveness (IR
methodsA comprehensive multimodal, high-dimensional strategy was applied to dissect the TIME of treatment-naive IR
resultsIR
conclusionThe production of lymphoid cell attracting and organizing chemokines by tumor-specific T cells in IR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.